bimekizumab (UCB4940) - UCB
Bimekizumab: Topline data from P3 BE OPTIMAL trial (NCT03895203) for psoriatic arthritis in H2 2021 (UCB) - Feb 21, 2020 - FY 2019 Results 
P3 data: top line
https://www.ucb.com/_up/ucb_com_ir/documents/2019%20FY%20press%20release%20-%20final.pdf
 
Feb 21, 2020
 
 
5207cd39-111a-4af7-8da4-0f166a610282.png